A cardiology team catalogues the injectable-peptide market, compound by compound
Three physicians at the University of Missouri-Kansas City and Saint Luke’s Mid America Heart Institute have published a review that does something the injectable-peptide market rarely gets: a compound-by-compound account of what is claimed, what mechanism is proposed, and what could go wrong. It covers BPC-157, TB-500, CJC-1295 and ipamorelin, MK-677, melanotan-II, GHK-Cu, retatrutide and … Read more